# A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

> **NCT00406809** · PHASE1,PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 81 (actual)

## Conditions studied

- Chronic Lymphoid Leukemia
- Lymphoid Malignancies
- Non-Hodgkin's Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** ABT-263

## Key facts

- **NCT ID:** NCT00406809
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00406809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00406809, "A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00406809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*